TY - JOUR
T1 - Current challenges in islet transplantation
AU - Leitão, Cristiane B.
AU - Cure, Pablo
AU - Tharavanij, Thipaporn
AU - Baidal, David A.
AU - Alejandro, Rodolfo
N1 - Funding Information:
Funding sources include the following: National Institutes of Health/National Center for Research Resources (U42 RR016603, M01RR16587); Juvenile Diabetes Research Foundation International (4-2000-946, 4-2004-361); National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (5 R01 DK55347, 5 R01 DK056953); State of Florida; and the Diabetes Research Institute Foundation (Hollywood, FL). Cristiane B. Leitão was the recipient of a scholarship from Conselho Nacional de Desen-volvimento Cientifico e Tecnologico (CNPq). No other potential conflicts of interest relevant to this article were reported.
PY - 2008/8
Y1 - 2008/8
N2 - Allogeneic islet transplantation is becoming a treatment option for patients with unstable type 1 diabetes melitus (T1DM). Around 80% of the islet recipients achieve insulin independence after one or two islet infusions under "Edmonton-like" immunosuppressive protocol, but only 10% will remain insulin independent over the long term. Islet transplantation leads to glucose stabilization, and severe hypoglycemia is prevented even in patients back on insulin injections. Thus, islet transplantation has achieved the proposed targets in patients with unstable T1DM: normalizing blood glucose and hemoglobin A1c, preventing severe hypoglycemic episodes, and improving quality of life. The current aims of islet transplantation programs are to maintain the success achieved and to overcome remaining obstacles and limitations.
AB - Allogeneic islet transplantation is becoming a treatment option for patients with unstable type 1 diabetes melitus (T1DM). Around 80% of the islet recipients achieve insulin independence after one or two islet infusions under "Edmonton-like" immunosuppressive protocol, but only 10% will remain insulin independent over the long term. Islet transplantation leads to glucose stabilization, and severe hypoglycemia is prevented even in patients back on insulin injections. Thus, islet transplantation has achieved the proposed targets in patients with unstable T1DM: normalizing blood glucose and hemoglobin A1c, preventing severe hypoglycemic episodes, and improving quality of life. The current aims of islet transplantation programs are to maintain the success achieved and to overcome remaining obstacles and limitations.
UR - http://www.scopus.com/inward/record.url?scp=52649127411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52649127411&partnerID=8YFLogxK
U2 - 10.1007/s11892-008-0057-3
DO - 10.1007/s11892-008-0057-3
M3 - Review article
C2 - 18631447
AN - SCOPUS:52649127411
VL - 8
SP - 324
EP - 331
JO - Current Diabetes Reports
JF - Current Diabetes Reports
SN - 1534-4827
IS - 4
ER -